Differential Signaling Pathways in Medulloblastoma: Nano-biomedicine Targeting Non-coding Epigenetics to Improve Current and Future Therapeutics

CONCLUSION: This review describes various MDB disease hallmarks, including the signaling mechanisms involved in pathophysiology, related-causal genes, epigenetics, downstream genes/epigenes, and possibly the causal disease genes/non-protein coding (nc)RNA/protein axis. Additionally, the challenges associated with MDB treatment are discussed, along with how they are being addressed using nano-technology and nano-biomedicine, with a listing of possible treatment options and future potential treatment modalities.PMID:38151840 | DOI:10.2174/0113816128277350231219062154

Source: Current Pharmaceutical Design - December 28, 2023 Category: Drugs & Pharmacology Authors: Daniil Sokolov Neha Sharda Aindrila Banerjee Kseniia Denisenko Emad B Basalious Hem Shukla Jaylyn Waddell Nadia M Hamdy Aditi Banerjee Source Type: research